Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43845   clinical trials with a EudraCT protocol, of which   7282   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Print Download

    Summary
    EudraCT Number:2016-001831-10
    Sponsor's Protocol Code Number:205667
    Clinical Trial Type:Outside EU/EEA
    Date on which this record was first entered in the EudraCT database:2018-02-23
    Trial results View results
    Index
    A. PROTOCOL INFORMATION
    B. SPONSOR INFORMATION
    C. APPLICANT IDENTIFICATION
    D. IMP IDENTIFICATION
    D.8 INFORMATION ON PLACEBO
    E. GENERAL INFORMATION ON THE TRIAL
    F. POPULATION OF TRIAL SUBJECTS
    G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL
    H.4 THIRD COUNTRY IN WHICH THE TRIAL WAS FIRST AUTHORISED
    Expand All   Collapse All
    A. Protocol Information
    A.2EudraCT number2016-001831-10
    A.3Full title of the trial
    An open-label, single arm, repeat dose, multi-centre study to evaluate the use of a safety syringe for the subcutaneous administration of mepolizumab in subjects with severe eosinophilic asthma (Study 205667)
    A.3.1Title of the trial for lay people, in easily understood, i.e. non-technical, language
    A Real-World Use Study of Safety Syringe for the Administration of Mepolizumab in Severe Asthma
    A.3.2Name or abbreviated title of the trial where available
    Ph3a study of SB240563 Safety Syringe in asthmatics
    A.4.1Sponsor's protocol code number205667
    A.7Trial is part of a Paediatric Investigation Plan No
    A.8EMA Decision number of Paediatric Investigation Plan
    B. Sponsor Information
    B.Sponsor: 1
    B.1.1Name of SponsorGlaxoSmithKline Research & Development Ltd
    B.1.3.4CountryUnited Kingdom
    B.3.1 and B.3.2Status of the sponsorCommercial
    B.4 Source(s) of Monetary or Material Support for the clinical trial:
    B.4.1Name of organisation providing supportGlaxoSmithKline Research & Development Ltd
    B.4.2CountryUnited Kingdom
    B.5 Contact point designated by the sponsor for further information on the trial
    B.5.1Name of organisationGlaxoSmithKline Research & Development Ltd
    B.5.2Functional name of contact pointGSK Clinical Support Help Desk
    B.5.3 Address:
    B.5.3.1Street Address1-3 Iron Bridge Road, Stockley Park West
    B.5.3.2Town/ cityUxbridge, Middlesex
    B.5.3.3Post codeUB11 1BT
    B.5.3.4CountryUnited Kingdom
    B.5.4Telephone number+44 (0)80 0 783 9733
    B.5.6E-mailGSKClinicalSupportHD@gsk.com
    D. IMP Identification
    D.IMP: 1
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation No
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameMepolizumab
    D.3.2Product code SB-240563
    D.3.4Pharmaceutical form Solution for injection in pre-filled syringe
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPSubcutaneous use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNMepolizumab
    D.3.9.1CAS number 196078-29-2
    D.3.9.2Current sponsor codeSB-240563
    D.3.9.3Other descriptive nameMEPOLIZUMAB
    D.3.9.4EV Substance CodeSUB21650
    D.3.10 Strength
    D.3.10.1Concentration unit mg/ml milligram(s)/millilitre
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number100
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin No
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) Yes
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.8 Information on Placebo
    E. General Information on the Trial
    E.1 Medical condition or disease under investigation
    E.1.1Medical condition(s) being investigated
    severe eosinophilic asthma
    E.1.1.1Medical condition in easily understood language
    Severe asthma
    E.1.1.2Therapeutic area Diseases [C] - Respiratory Tract Diseases [C08]
    MedDRA Classification
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 20.0
    E.1.2Level PT
    E.1.2Classification code 10003553
    E.1.2Term Asthma
    E.1.2System Organ Class 10038738 - Respiratory, thoracic and mediastinal disorders
    E.1.3Condition being studied is a rare disease No
    E.2 Objective of the trial
    E.2.1Main objective of the trial
    To assess the use of the combination product, mepolizumab liquid drug
    product in safety syringe for the subcutaneous self-administration of
    mepolizumab by subjects with severe eosinophilic asthma
    E.2.2Secondary objectives of the trial
    To assess the use of mepolizumab liquid drug product in safety syringe
    outside the clinic setting.
    E.2.3Trial contains a sub-study No
    E.3Principal inclusion criteria
    A subject will be eligible for inclusion in this study only if all of the following criteria apply:
    AGE
    1. Age: At least 12 years of age inclusive, at the time of signing the informed consent. [For those countries where local regulations permit enrolment of adults only, subject recruitment will be restricted to those who are ≥18 years of age]
    TYPE OF SUBJECT AND DIAGNOSIS INCLUDING DISEASE SEVERITY
    2. Asthma: A physician diagnosis of asthma for ≥2 years that meets the
    National Heart, Lung and Blood Institute guidelines [National heart, lung
    and blood institute (NIH), 2007] or Global Initiative for Asthma (GINA)
    guidelines [GINA, 2015]
    3. Mepolizumab treatment:
    a. Not receiving mepolizumab treatment at Visit 1 (NB: these subjects must also meet inclusion criteria 4, 5, 6 and 7).
    OR
    b. Receiving 100 mg SC mepolizumab administered for the treatment of severe eosinophilic asthma every 4 weeks for at least 12 weeks prior to
    Visit 1.
    The following inclusion criteria are only applicable to those subjects NOT
    receiving mepolizumab treatment at Visit 1:
    4. Eosinophilic asthma: A high likelihood of eosinophilic asthma as per
    the required 'Continuation to Treatment' - Criterion 2.
    5. Inhaled Corticosteroid: A well-documented requirement for regular
    treatment with high dose inhaled corticosteroid (ICS) in the 12 months
    prior to Visit 1 with or without maintenance oral corticosteroids (OCS).
    -For subjects ≥18 years old:
    -ICS dose must be ≥880 mcg/day fluticasone propionate (FP) (exactuator) or equivalent daily.
    -For ICS/long-acting-beta-2-agonist (LABA) combination
    preparations, the highest approved maintenance dose in the local country will meet this ICS criterion.
    - For subjects ≥12 to ≤17 years old:
    -ICS dose must be ≥440 μg/day FP (ex-actuator) or equivalent daily.
    -For ICS/LABA combination preparations, the mid-strength approved
    maintenance dose in the local country will meet this ICS criterion.
    6. Controller Medication: Current treatment with an additional controller
    medication, besides ICS, for at least 3 months or a documented failure in
    the past 12 months of an additional controller medication [e.g., longacting
    beta-2-agonist (LABA), leukotriene receptor antagonist (LTRA), or
    theophylline] for at least 3 successive months.
    7. Exacerbation history: Previously confirmed history of one or more
    exacerbations requiring treatment with systemic corticosteroid (CS)
    [intramuscular (IM), intravenous, or oral] in the 12 months prior to Visit 1, despite the use of high-dose ICS. For subjects receiving maintenance CS, the CS treatment for an exacerbation must have been a two-fold dose increase or greater.
    WEIGHT
    8. Body weight: A minimum ≥40 kg at Visit 1
    SEX
    9. Gender: Male or Female
    Females:
    A female subject is eligible to participate if she is not pregnant (as
    confirmed by a negative urine human chorionic gonadotrophin (hCG) test), planning to become pregnant during the time of study participation (and up to 16 weeks after the last dose), not lactating, and at least one of the following conditions applies:
    a. Non-reproductive potential defined as:
    -Pre-menopausal females with one of the following:
    -Documented tubal ligation
    -Documented hysteroscopic tubal occlusion procedure with follow-up confirmation of bilateral tubal occlusion
    -Hysterectomy
    -Documented Bilateral Oophorectomy
    -Postmenopausal female (see Appendix 3 for specific criteria).
    b. Reproductive potential and agrees to follow one of the options listed
    in the Modified List of Highly Effective Methods for Avoiding Pregnancy in
    Females of Reproductive Potential (FRP) (see Appendix 3) from 30 days
    prior to the first dose of study medication and until 16 weeks after the
    last dose of study medication and completion of the End of Study/Early
    Withdrawal visit. The investigator is responsible for ensuring that
    subjects understand how to properly use these methods of contraception.
    INFORMED CONSENT
    10. Informed Consent: Capable of giving signed informed consent which
    includes compliance with the requirements and restrictions listed in the consent form and in this protocol.
    E.4Principal exclusion criteria
    A subject will not be eligible for inclusion in this study if any of the following criteria apply:
    CONCURRENT CONDITIONS/MEDICAL HISTORY (INCLUDES LIVER
    FUNCTION AND QTc INTERVAL)
    1. Concurrent Respiratory Disease: Presence of a known pre-existing,
    clinically important lung condition other than asthma. This includes
    current infection, bronchiectasis, pulmonary fibrosis, bronchopulmonary
    aspergillosis, or diagnoses of emphysema or chronic bronchitis (chronic
    obstructive pulmonary disease other than asthma) or a history of lung cancer.
    2. Eosinophilic Diseases: Subjects with other conditions that could lead
    to elevated eosinophils such as Hypereosinophilic Syndromes, including
    Churg-Strauss Syndrome, or Eosinophilic Esophagitis. Subjects with a
    known, pre-existing parasitic infestation within 6 months prior to Visit 1
    are also to be excluded.
    3. Malignancy: A current malignancy or previous history of cancer in
    remission for less than 12 months prior to screening (Subjects that had
    localized carcinoma of the skin which was resected for cure will not be
    excluded).
    4. Immunodeficiency: A known immunodeficiency (e.g. human
    immunodeficiency virus – HIV), other than that explained by the use of
    corticosteroids taken as therapy for asthma.
    5. Other Concurrent Medical Conditions: Subjects who have known, preexisting,
    clinically significant cardiovascular, endocrine, autoimmune,
    metabolic, neurological, renal, gastrointestinal, hepatic, haematological
    or any other system abnormalities that are uncontrolled with standard
    treatment.
    6. Liver Disease: Known, pre-existing, unstable liver disease (as defined by the presence of ascites, encephalopathy, coagulopathy,
    hypoalbuminaemia, esophageal or gastric varices or persistent
    jaundice), cirrhosis, and known biliary abnormalities (with the exception of Gilbert's syndrome or asymptomatic gallstones).
    7. ECG Assessment: QT interval corrected for heart rate by either
    Fridericia's or Bazett's formula QTc(F)/QTc(B) ≥450msec or
    QTc(F)/QTc(B) ≥480 msec for subjects with Bundle Branch Block at Visit 1.
    CONCOMITANT MEDICATIONS
    8. Xolair: Subjects who have received omalizumab within 130 days of
    Visit 1.
    9. Other Monoclonal Antibodies not including mepolizumab: Subjects
    who have received any monoclonal antibody (other than Xolair) to treat
    inflammatory disease within 5 half-lives of Visit 1.
    10. Investigational Medications: Subjects who have received treatment
    with an investigational drug, other than mepolizumab within the past 30
    days or five terminal phase half-lives of the drug whichever is longer,
    prior to visit 1 (this also includes investigational formulations of
    marketed products) or experimental anti-inflammatory drugs (non biologicals) in the past 3 months.
    11. Chemotherapy: Subjects who have received chemotherapy within 12
    months prior to Visit 1.
    CONTRAINDICATIONS
    13. Hypersensitivity: Subjects with hypersensitivity to mepolizumab or
    to any of the excipients (sodium phosphate, citric acid, sucrose, EDTA, polysorbate 80).
    DIAGNOSTIC ASSESSMENTS AND OTHER CRITERIA
    14. Adherence: Subjects who have known evidence of lack of adherence
    to controller medications and/or ability to follow physician's recommendations.
    E.5 End points
    E.5.1Primary end point(s)
    Proportion of subjects successfully able to self-administer their observed
    third dose
    E.5.1.1Timepoint(s) of evaluation of this end point
    Week 8
    E.5.2Secondary end point(s)
    Proportion of subjects successfully able to self-administer their unobserved second dose outside the clinic setting
    E.5.2.1Timepoint(s) of evaluation of this end point
    Week 4
    E.6 and E.7 Scope of the trial
    E.6Scope of the trial
    E.6.1Diagnosis No
    E.6.2Prophylaxis No
    E.6.3Therapy No
    E.6.4Safety Yes
    E.6.5Efficacy No
    E.6.6Pharmacokinetic Yes
    E.6.7Pharmacodynamic Yes
    E.6.8Bioequivalence No
    E.6.9Dose response No
    E.6.10Pharmacogenetic Yes
    E.6.11Pharmacogenomic No
    E.6.12Pharmacoeconomic No
    E.6.13Others Yes
    E.6.13.1Other scope of the trial description
    Correct use of the device
    E.7Trial type and phase
    E.7.1Human pharmacology (Phase I) No
    E.7.1.1First administration to humans No
    E.7.1.2Bioequivalence study No
    E.7.1.3Other No
    E.7.1.3.1Other trial type description
    E.7.2Therapeutic exploratory (Phase II) No
    E.7.3Therapeutic confirmatory (Phase III) Yes
    E.7.4Therapeutic use (Phase IV) No
    E.8 Design of the trial
    E.8.1Controlled No
    E.8.1.1Randomised No
    E.8.1.2Open Yes
    E.8.1.3Single blind No
    E.8.1.4Double blind No
    E.8.1.5Parallel group No
    E.8.1.6Cross over No
    E.8.1.7Other Yes
    E.8.1.7.1Other trial design description
    An open-label, single arm, repeat dose, multi-centre study
    E.8.2 Comparator of controlled trial
    E.8.2.1Other medicinal product(s) No
    E.8.2.2Placebo No
    E.8.2.3Other No
    E.8.2.4Number of treatment arms in the trial1
    E.8.3 Will this trial be conducted at a single site globally? No
    E.8.4 Will this trial be conducted at multiple sites globally? Yes
    E.8.6 Trial involving sites outside the EEA
    E.8.6.2Trial being conducted completely outside of the EEA No
    E.8.6.3Specify the countries outside of the EEA in which trial sites are planned
    Canada
    Russian Federation
    United States
    E.8.7Trial has a data monitoring committee No
    E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial
    LSLV
    E.8.9 Initial estimate of the duration of the trial
    E.8.9.2In all countries concerned by the trial months9
    F. Population of Trial Subjects
    F.1 Age Range
    F.1.1Trial has subjects under 18 Yes
    F.1.1Number of subjects for this age range: 1
    F.1.1.1In Utero No
    F.1.1.2Preterm newborn infants (up to gestational age < 37 weeks) No
    F.1.1.3Newborns (0-27 days) No
    F.1.1.4Infants and toddlers (28 days-23 months) No
    F.1.1.5Children (2-11years) No
    F.1.1.6Adolescents (12-17 years) Yes
    F.1.1.6.1Number of subjects for this age range: 1
    F.1.2Adults (18-64 years) Yes
    F.1.2.1Number of subjects for this age range: 42
    F.1.3Elderly (>=65 years) Yes
    F.1.3.1Number of subjects for this age range: 12
    F.2 Gender
    F.2.1Female Yes
    F.2.2Male Yes
    F.3 Group of trial subjects
    F.3.1Healthy volunteers No
    F.3.2Patients Yes
    F.3.3Specific vulnerable populations Yes
    F.3.3.1Women of childbearing potential not using contraception No
    F.3.3.2Women of child-bearing potential using contraception Yes
    F.3.3.3Pregnant women No
    F.3.3.4Nursing women No
    F.3.3.5Emergency situation No
    F.3.3.6Subjects incapable of giving consent personally No
    F.3.3.7Others No
    F.4 Planned number of subjects to be included
    F.4.2 For a multinational trial
    F.4.2.2In the whole clinical trial 55
    F.5 Plans for treatment or care after the subject has ended the participation in the trial (if it is different from the expected normal treatment of that condition)
    The investigator is responsible for ensuring that consideration has been given to the poststudy care of the subject's medical condition, whether or not GSK is providing specific post-study treatment. There are no plans to provide mepolizumab following study completion.
    G. Investigator Networks to be involved in the Trial
    H.4 Third Country in which the Trial was first authorised
    H.4.1Third Country in which the trial was first authorised: Canada
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri Apr 19 01:56:54 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA